A study published in a supplement to the Journal of Women's Health looks to the widespread impact of newer screening technologies to improve outcomes.
One of every 7 women who undergo annual mammography screening for will be called back for follow-up tests.
These women can worry for days or weeks that the "suspicious" finding the radiologist has seen on their mammogram will be cancer. They might also incur direct and indirect medical costs.
A supplement to the September issue of the Journal of Women's Health highlights the burden, both financial and personal, of screening recall, and outlines some of the newer technologies for imaging the breast that could improve the accuracy of screening and make it more cost efficient.
"Our goal in is to find the most cancers at the lowest cost," Susan C. Harvey, MD, from Johns Hopkins Medical Institutions in Baltimore, told Medscape Medical News. "We want to up our value."
Link to report on Medscape: http://bit.ly/1mYRNe0
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More